Another study performed in Japanese patients with DM type 2 revealed that administration of SGLT2 inhibitors for greater than 180 days (about 6 months) has a positive association with lowering the risk of developing pancreatic cancer (adjusted odds ratio: 0.58, 95% confidence interval: 0.31–0.99) [32]. The gene discussed is SLC5A2; the disease is familial pancreatic carcinoma.